GlassScriptPhysician profile
Benjamin H Greiner
NPI 1902428212
$3,568.83
in general payments reported to CMS, 2019-2025
26 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,000 · 2023: $197 · 2024: $1,220 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $441.09 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $351.51 | 2023-2025 | Wegovy |
| Glaxosmithkline, LLC. | $254.80 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $233.76 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.42 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $135.12 | 2024-2025 | Veozah |
| Lilly USA, LLC | $133.38 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $118.56 | 2024-2025 | |
| Eisai INC. | $74.78 | 2024-2025 | |
| Amgen INC. | $73.08 | 2024-2025 | Repatha, Otezla, Evenity |
| Daiichi Sankyo INC. | $62.05 | 2025 | Injectafer |
| Sumitomo Pharma America, INC. | $58.06 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $57.04 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $54.37 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.29 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $40.53 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $39.21 | 2024-2025 | Rexulti |
| Dexcom, INC. | $38.90 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.37 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $25.86 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $19.29 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Azurity Pharmaceuticals, INC. | $19.28 | 2025 | Alvesco |
| Gilead Sciences, INC. | $18.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.58 | 2025 | Trintellix |
| Lexicon Pharmaceuticals, INC. | $14.73 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Greiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.